

XbaI Asel
 1 CTCGAGAGCGGGCAGTGAGCGAACGCAATTAAATGTGAGTTAGCTCACTCATTAGGCACCCAGGCTTACACTTAT
 79 GCTCCGGCTCGTATGTTGGAATTGTGAGCGGATAACAAATTACACAGAAATTCAATTAAAGAGGAGAAATTAAAC
 PeiB leader AlwNI EcoRI RBS
 157 CATGAAATACCTATTGCCTACGGCAGCCGCTGGCTTGCTGCTGGCAGCTCAGCCGCCATGGCGCAGGTGCAGCTG
 1 MetAlaGlnValGlnLeu

VH anti-CD16 EcoRV
 235 CAGCAGTCTGGAGCTGAGCTGGTAAGGCCTGGACTTCAGTGAAGATATCCTGCAAGGCTTCTGGCTACACCTTCACT
 7 GlnGlnSerGlyAlaGluLeuValArgProGlyThrSerValLysIleSerCysLysAlaSerGlyTyrThrPheThr
 CDR-H1 EcoRV CDR-H2
 313 AACTACTGGCTAGGTTGGGTAAAACAGAGGCCCTGGACATGGACTCGAGTGGATTGGAGATATCTACCCCTGGAGGTGGT
 33 AsnTyrTrpLeuGlyTrpValLysGlnArgProGlyHisGlyLeuGluTrpIleGlyAspIleTyrProGlyGlyGly
 391 TATACTAACTACAATGAGAAATTCAAGGCCAACAGTGCAGACACATCCTCAGAACACTGCCTACGTGCAG
 59 TyrThrAsnTyrAsnGluLysPheLysGlyLysAlaThrValThrAlaAspThrSerArgThrAlaTyrValGln
 CDR-H3

469 GTCAGGAGCCTGACATCTGAGGACTCTGCTGTCTATTCTGTGCAAGATCGGCTAGCTGGTACTTCGATGTCTGGGC
 85 ValArgSerLeuThrSerGluAspSerAlaValTyrPheCysAlaArgSerAlaSerTrpTyrPheAspValTrpGly
 CH1 HindIII Linker EcoRV

547 GCACGGACTACGGTCACCGTCTCCTCAGCCAAAACAACACCCAAGCTTGGCGGTGATATCGAGCTCACTCAGTCTCCA
 111 AlaArgThrThrValThrValSerSerAlaLysThrProLysLeuGlyGlyAspIleGluLeuThrGlnSerPro

VL anti-CD30
 625 AAATTATGTCCACATCAGTAGGACACAGGGTCAACGTACCTACAAGGCCAGTCAGAATGTGGGTACTAATGTAGCC
 137 LysPheMetSerThrSerValGlyAspArgValAsnValThrTyrLysAlaSerGlnAsnValGlyThrAsnValAla
 703 TGGTTCAACAAAACCAGGGCAATCTCTAAAGTTCTGATTACTCGGCATCTTACCGATACAGTGGAGTCCCTGAT
 163 TrpPheGlnGlnLysProGlyGlnSerProLysValLeuIleTyrSerAlaSerTyrArgTyrSerGlyValProAsp
 781 CGCTTCACAGGCAGTGGATCTGGAACAGATTCTCACCATCAGCAATGTGCAGTCTGAAGACTTGGCAGAGTAT
 189 ArgPheThrGlySerGlyThrAspPheThrLeuThrIleSerAsnValGlnSerGluAspLeuAlaGluTyr
 C kappa NotI

859 TTCTGTCAGCAATATCACACCTATCCTCTCACGTCGGAGGGGGCACCAAGCTGAAATCAAACGGGCTGATGCTGCG
 215 PheCysGlnGlnTyrHisThrTyrProLeuThrPheGlyGlyGlyThrLysLeuGluIleLysArgAlaAspAlaAla
 BamHI c-myc epitope His6 tail BgIII

937 GCCGCTGGATCCGAACAAAAGCTGATCTCAGAAGAAGACCTAAACTCACATCACCACATCACCACATCACTAAAGATCTATT
 241 AlaAlaGlySerGluGlnLysLeuIleSerGluGluAspLeuAsnSerHisHisHisHisHis

RBS Pel B leader NcoI
 1015 AAAGAGGAGAAATTAAACCATGAAATACCTATTGCCTACGGCAGCCGCTGGCTTGCTGCTGGCAGCTCAGCCGCC
 NcoI Serum A VH anti-CD30

1093 ATGGCGGCCATGGCCCAGGTGCAACTGCAGCAGTCAGGGCTGAGCTGGCTAGACCTGGGGCTTCAGTGAAGATGTCC
 1 MetAlaGlnValGlnLeuGlnGlnSerGlyAlaGluLeuAlaArgProGlyAlaSerValLysMetSer

1171 TGCAAGGCTCTGGCTACACCTTACTACCTACACAATACACTGGGTAAGACAGAGGCCCTGGACACGATCTGGAATGG
 24 CysLysAlaSerGlyTyrThrPheThrThrTyrIleHisTrpValArgGlnArgProGlyHisAspLeuGluTrp

1249 ATTGGATACATTAATCCTAGCAGTGGATATTCTGACTACAATCAGAACTTCAAGGGCAAGACCACATGACTGCAGAC
 50 IleGlyTyrIleAsnProSerSerGlyTyrSerAspTyrAsnGlnAsnPheLysGlyLysThrThrLeuThrAlaAsp

1327 AAGTCCTCCAACACAGCCTACATGCAACTGAACAGCCTGACATCTGAGGACTCTGGGTCTATTACTGTGCAAGAAGA
 76 LysSerSerAsnThrAlaTyrMetGlnLeuAsnSerLeuThrSerGluAspSerAlaValTyrTyrCysAlaArgArg
 CH1

1405 GCGGACTATGGTAACACGAATATACCTGGTTGCTTACTGGGGCAAGGGACCACGGTCACCGTCTCCTCAGCCAAA
 102 AlaAspTyrGlyAsnTyrGluTyrThrTrpPheAlaTyrTrpGlyGlnGlyThrThrValThrValSerAlaLys
 HindIII Linker EcoRV VL anti-CD16

1483 ACAACACCCAAGCTTGGCGGTGATATCCAGGCTGTTGACTCAGGAATCTGCACTCACCACATCACCTGGTGAAAC
 128 ThrThrProLysLeuGlyGlyAspIleGlnAlaValValThrGlnGluSerAlaLeuThrThrSerProGlyGluTh
 CDR-L1

1560 AGTCACACTCACTTGTGCTCAAATACTGGGACTGTTACAACACTGAACTATGCCAACTGGGTCCAAGAAAAACAGA
 153 rValThrLeuThrCysArgSerAsnThrGlyThrValThrSerAsnTyrAlaAsnTrpValGlnGluLysProAs
 CDR-L2

1638 TCATTTTATTCACTGGTCTAATAGGTCAACCAACAAACCGAGCTCCAGGTGTTCTGCCAGATTCTCAGGCTCCCTGAT
 179 pHisLeuPheThrGlyLeuIleGlyHisThrAsnArgAlaProGlyValProAlaArgPheSerGlySerLeuI
 CDR-L3

1716 TGGAGACAAGGCTGCCCTCACCATCACAGGGCACAGACTGAGGATGAGGAATATATTCTGTGCTTATGGTATAA
 205 eGlyAspLysAlaAlaLeuThrIleThrGlyAlaGlnThrGluAspGluAlaIleTyrPheCysAlaLeuTrpTyrAs
 NotI BamHI

1794 CAACCATTGGTGGTGGTGGAGGAACCAAACACTGACTGTCCTAGGCCAGCCAAAGTCTGCGGCCGCTGGATCCGAACA
 231 nAsnHisTrpValPheGlyGlyGlyThrLysLeuThrValLeuGlyGlnProLysSerAlaAlaGlySerGluG1

c-myc epitope


		His6 tail	XbaI	BclI	NheI
1872	AAAGCTGATCTCAGAAGAAGACCTAAACTCACATCACCATCACACTAAATCTAGAGGCCCTGTGCTAATGATCAGC				
2577	nLysLeuIleSerGluGluAspLeuAsnSerHisHisHisHisHisHis				
1950	TAGCTTGAGGCATCAATAAAACGAAAGGCTCAGTCGAAAGACTGGGCCCTTCGTTTATCTGTTGTTGTCGGTTAAC				HpaI
SaI	Earl	PvuI	FspI	BglI	
2028	GTGACCTGGCGTAATAGCGAAGAGGCCGACCGATGCCCTCCAACAGTGGCGAGCCTGAATGGGAATGGGA				
2106	CGGCCCTGTAGCGCGCATTAAGCGGGGGGTGTGGTGGTACGCGCAGCGTACACTGCCAGCGCCT				
			NaeI		
2184	AGCGCCCGCTCTTCGCTTTCTCCCTTCGACGTTGCCACGTTGCCGGCTTCCCCGTCAGCTCTAAATCGGGG				
	f1 IR				
2262	GCTCCCTTGTAGGGTTCCGATTTAGTCGTTTACGGCACCTCGACCCCAAAAAACTTGATTAGGGTGTGGTACCGTAG				
2340	TGGGCCATGCCCTGATAGACGGTTTTCGCCCTTGACGTTGGAGTCCACGTTTAATAGTGGACTCTGTTCCA				
2418	AACTGGAAACAACACTCAACCCTATCTCGGTCTATTCTTTGATTATAAGGGATTIGCGGATTGCCCTATTGGTT				
			SspI		
2496	AAAAAATGAGCTGATTTAACAAAAATTAAACGCAATTAAACAAAATTAAACGCTTACAATTAGGTGGCACTTTT				
			BspHI		
2574	CGGGGAAATGTGCCGGAACCCCTATTGTTTCTAAATACATTCAAATATGTATCCCTCATGAGACAATAA				
	SspI	Earl			
2652	CCCTGATAAAATGCTCAATAATATTGAAAAGGAAGAGTATGAGTATTCAACATTCCGTGTCGCCCTATTCCCTT				Apal
2730	TTTGCUGCATTTCGCTTCCCTGTTTGCTCACCCAGAAACGCTGGTGAAGTAAAAGATGCTGAAGATCAGTTGGGT				
			XmnI		
2808	GCACGAGTGGGTTACATCGAACTGGATCTCAACAGCGTAAGATCCTGAGAGTTGCCCGAAGAACGTTTCCA				
	DraI				
2886	ATGATGAGCACTTTAAAGTTCTGCTATGTGGCGGGTATTATCCGTATTGACGCCGGCAAGAGCAACTCGGTCGC				1000
		Scal			
2964	CGCATAACACTATTCTCAGAATGACTTGTTGAGTACTCACCAGTCACAGAAAAGCATCTACGGATGGCATGACAGTA				
	β -Lactamase				
			PvuI		
3042	AGAGAATTATGAGCTGCTGCATAACCATGAGTGATAACACTGCGGCCACTTACTTGACAAACGATCGGAGGACCG				
3120	AAGGAGCTAACCGCTTTTGACAAACATGGGGATCATGTAACCGCTTGATGGAAACGGAGCTGAATGAA				
			FspI		
3198	GCCATACCAAACGACGAGCGTGACACCAACGATGCCGTAGCAATGGCAACACGTTGCCAAACTATTAACTGGCGAA				
		Asel			
3276	CTACTTACTCTAGCTTCCCGCAACAAATTAAATAGACTGGATGGAGGCGATAAAGTTGCAAGGACCACTCTGCGCTCG				
	BglI		BsaI		
3354	GCCCTCCGGCTGGCTGGTTATTGCTGATAAAATCTGGAGCCGGTGAGCGTGGGCTCGCGGTATCATTGCAAGCAGT				
3432	GGGCCAGATGGTAAGCCCTCCGTATCGTAGTTACTACACGACGGGAGTCAGGCAACTATGGATGAACGAAATAGA				
3510	CAGATCGCTGAGATAGGTGCCCTACTGATTAAGCATTGTAACTGTCAGACCAAGTTACTCATATATACTTTAGATT				
	DraI	DraI	BspHI		
3588	GATTTAAAACCTCATTAAATTAAAAGGATCTAGGTGAAGATCCTTTTGATAATCTCATGACCAAAATCCCTTAA				
3666	CGTAGTTTCGTTCCACTGAGCGTCAGACCCCGTAGAAAAGATCAAAGGATCTTCTTGAGATCCTTTCTGCGC				
3744	GTAATCTGCTGTTGCAAACAAAAAACCAACCGCTACCGAGCGGTGGTTGCTGGATCAAGAGCTACCAACTCTT				
3822	TTTCCGAAGGTAACGGCTTCAGCAGAGCGCAGATACCAAATACTGTCCTCTAGTGTAGCCGTAGTTAGGCCACCAC				
			AlwNI		
3900	TTCAAGAACTCTGTTAGCACCGCCTACATACCTCGCTCTGCTAATCCTGTTACCAAGTGGCTGCTGCCAGTGGCGATAAG				
	ColE1		2000		ApalI
3978	TCTGTCCTTACCGGGTTGGACTCAAGACGATAGTTACCGGATAAGGCGCAGCGGTGGCTGAACGGGGGGTTCGTGC				
4056	ACACAGCCCAGCTTGGAGCGAACGACCTACACCGAACACTGAGATACTACAGCGTGAGCTATGAGAAAGCGCCACGCTT				
4134	CCCGAAGGGAGAAAGCGGACAGGTATCCGTAAGCGCAGGGTGGGAACAGGAGAGCGCAGCGAGGGAGCTTCCAGGG				
4212	GGAAACGCCCTGGTATCTTATAGTCCTGCGGTTCGCCACCTCTGACTTGAGCGTCGATTGTTGATGCTCGTCA				
4290	GGGGGGCGGAGCCTATGGAAAAACGCCAGCAACGCCGCTTTTACGGTTCTGCCCTTTGCTGCCCTTTGCTCAC				
4368	ATGTTCTTCCTGCCATTCCCTGATTCGAGTACCGTATTACGCCCTTGAGTGAGCTGATACCGCTCGCCGC				
		Earl			
4446	AGCCGAACGACCGAGCGCAGCGAGTCAGTGAGCGAGGAAGCGGAAGAGCGCCAAACGCCCTCCCCCGCG				
	Asel	BspMI			
4524	CGTTGGCCGATTCAATTGAGGTATCACGAGGCCCTTCGTCTTCAC				

Fig. 1 (cont'd)




Fig. 2

Granulocytes (CD16⁺)

Neg. Control

L540CY cells (CD30⁺)

Neg. Control

F_v antibody construct
according to the inventionF_v antibody construct
according to the invention

Fluorescence Intensity

Fig. 3




Fig. 4

